Ligand Pharmaceuticals Stock Options
| LGND Stock | USD 116.55 2.09 1.76% |
Ligand Pharmaceuticals' latest option contracts expiring on March 21st 2025 are carrying combined implied volatility of 0.54 with a put-to-call open interest ratio of 0.29 over 27 outstanding agreements suggesting investors are buying way more calls than puts on contracts expiring on March 21st 2025. The total put volume is at 2.0, with calls trading at the volume of 6.0. This yields a 0.33 put-to-call volume ratio.
Open Interest Against March 21st 2025 Option Contracts
2025-03-21
The chart above shows Ligand Pharmaceuticals' distribution of open interest by maturity on contracts that have not yet been settled. The area between the two highest points is the projection of the price at expiration. Ligand Pharmaceuticals' open interest chart also provides vital information regarding the liquidity of an option. If there is no open interest for Ligand Pharmaceuticals' option, there is no secondary market available for investors to trade.
In The Money vs. Out of Money Option Contracts on Ligand Pharmaceuticals
Analyzing Ligand Pharmaceuticals' in-the-money options over time can help investors to take a profitable long position in Ligand Pharmaceuticals regardless of its overall volatility. This is especially true when Ligand Pharmaceuticals' options are deep in the money. These options can be identified using deltas that are over 0.75. Deep in-the-money Ligand Pharmaceuticals' options could be used as guardians of the underlying stock as they move almost dollar for dollar with Ligand Pharmaceuticals' stock while costing only a fraction of its price.
Ligand Pharmaceuticals' stock options are financial instruments that give investors the right to buy or sell shares of Ligand Pharmaceuticals common stock at a specified price for a given time period. Generally speaking, an option to purchase or sell Ligand stock makes it part of the underlying stock when the option's price is tied to the movement of the underlying stock. If Ligand Pharmaceuticals' stock price goes up or down, the stock options follow.
At present, Ligand Pharmaceuticals' Liabilities And Stockholders Equity is projected to increase significantly based on the last few years of reporting. Ligand Pharmaceuticals In The Money Call Balance
When Ligand Pharmaceuticals' strike price is surpassing the current stock price, the option contract against Ligand Pharmaceuticals Incorporated stock is said to be in the money. When it comes to buying Ligand Pharmaceuticals' options that are 'In the Money' or 'Out of the Money', the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
While 'out-of-the-money' option contracts written on Ligand Pharmaceuticals Incorporated are typically viewed as the more aggressive, there are potential upsides to purchasing these types of options contracts. For one, the cost to buy an 'Out of the Money' option is lower than the cost to buy an 'In the Money' option. This cost-benefit is due to the fact that at the time of the purchase, 'Out of the Money' contracts have no intrinsic value. So, while the potential for a 100% loss is more significant, the cost and risk to enter the trade are lower.
Ligand Current Options Market Mood
Ligand Pharmaceuticals' open interest and total value indicators provide investors with the necessary information to digest the overall options buildup for its expiring contracts. In addition, it helps Ligand Stock's traders understand whether a recent fall or rise in the market is unreasonable and if the time has come to take contrarian positions. These ratios are calculated based on options trading volumes and current open interest.
Put-to-Call Open Interest
Put-to-Call Volume
Unfortunately, most Ligand Pharmaceuticals' options investors are not very successful. Ligand Pharmaceuticals' option open interest and volume spread between outstanding puts and calls are regarded by many investors as reliable indicators of the overall future market direction.
Rule 16 of the current Ligand contract
Base on the Rule 16, the options market is currently suggesting that Ligand Pharmaceuticals Incorporated will have an average daily up or down price movement of about 0.0338% per day over the life of the 2025-03-21 option contract. With Ligand Pharmaceuticals trading at USD 116.55, that is roughly USD 0.0393. If you think that the market is fully incorporating Ligand Pharmaceuticals' daily price movement you should consider buying Ligand Pharmaceuticals Incorporated options at the current volatility level of 0.54%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Ligand |
Purchasing Ligand Pharmaceuticals options can give investors a meaningful hedge against losses and, therefore, could be used conservatively to decrease the volatility of your portfolio. However, many options could also amount to little more than gambling, significantly enhancing your overall portfolio risk. One simple example of these aggressive strategies is the sale of "uncovered" Ligand calls. Remember, the seller must deliver Ligand Pharmaceuticals Incorporated stock to the call owner when a call is exercised.
Ligand Pharmaceuticals Option Chain
When Ligand Pharmaceuticals' strike price is surpassing the current stock price, the option contract against Ligand Pharmaceuticals Incorporated stock is said to be in the money. When it comes to buying options that are ITM or OTM, the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
Ligand Pharmaceuticals' option chain is a display of a range of information that helps investors for ways to trade options on Ligand. In general, an option chain provides a helpful tool for investors to see all available option contracts, both puts, and calls, for Ligand. It also shows strike prices and maturity days for a Ligand Pharmaceuticals against a given expiration period. The table below combines all the option information in the form of a chain but before you use it, remember that it entails significant risk and it is not for everyone. | Open Int | Strike Price | Current Spread | Last Price | |||
Call | LGND250321C00090000 | 2 | 90.0 | 27.5 - 31.8 | 26.1 | In |
Call | LGND250321C00115000 | 1 | 115.0 | 7.6 - 12.0 | 8.75 | In |
Call | LGND250321C00120000 | 9 | 120.0 | 5.3 - 9.0 | 6.71 | Out |
Call | LGND250321C00125000 | 2 | 125.0 | 2.7 - 7.0 | 4.7 | Out |
Call | LGND250321C00130000 | 0 | 130.0 | 1.75 - 4.0 | 3.5 | |
Call | LGND250321C00135000 | 0 | 135.0 | 0.3 - 4.6 | 2.45 | |
Call | LGND250321C00140000 | 0 | 140.0 | 0.2 - 4.9 | 0.2 | |
Call | LGND250321C00145000 | 0 | 145.0 | 0.0 - 4.5 | 4.5 | |
Call | LGND250321C00150000 | 0 | 150.0 | 0.0 - 4.8 | 4.8 | |
Call | LGND250321C00155000 | 0 | 155.0 | 0.0 - 4.8 | 4.8 | |
Call | LGND250321C00160000 | 0 | 160.0 | 0.0 - 4.8 | 4.8 | |
Call | LGND250321C00165000 | 0 | 165.0 | 0.0 - 4.8 | 4.8 | |
Call | LGND250321C00170000 | 0 | 170.0 | 0.0 - 4.8 | 4.8 | |
Put | LGND250321P00095000 | 1 | 95.0 | 0.1 - 4.9 | 1.6 | Out |
Put | LGND250321P00100000 | 1 | 100.0 | 0.1 - 4.9 | 2.18 | Out |
Put | LGND250321P00110000 | 1 | 110.0 | 1.5 - 4.9 | 3.15 | Out |
Put | LGND250321P00115000 | 1 | 115.0 | 3.1 - 7.7 | 4.95 | Out |
Put | LGND250321P00125000 | 0 | 125.0 | 8.4 - 13.0 | 8.4 | In |
Put | LGND250321P00130000 | 0 | 130.0 | 11.8 - 16.5 | 11.8 | In |
Put | LGND250321P00135000 | 0 | 135.0 | 15.9 - 20.0 | 15.9 | In |
Put | LGND250321P00140000 | 0 | 140.0 | 20.3 - 24.5 | 20.3 | In |
Put | LGND250321P00145000 | 0 | 145.0 | 25.2 - 29.0 | 25.2 | In |
Put | LGND250321P00150000 | 0 | 150.0 | 29.6 - 33.5 | 29.6 | In |
Put | LGND250321P00155000 | 0 | 155.0 | 34.4 - 38.5 | 34.4 | In |
Put | LGND250321P00160000 | 0 | 160.0 | 39.4 - 43.5 | 39.4 | In |
Put | LGND250321P00165000 | 0 | 165.0 | 44.3 - 49.0 | 44.3 | In |
Put | LGND250321P00170000 | 0 | 170.0 | 49.2 - 53.5 | 49.2 | In |
Ligand Pharmaceuticals Market Cap Over Time
Market Cap |
| Timeline |
Ligand Total Stockholder Equity
Total Stockholder Equity |
|
Ligand Pharmaceuticals Corporate Management
| Vincent Antle | Senior Capitsol | Profile | |
| Paul Hadden | Senior Development | Profile | |
| Michael Jeong | Head Relations | Profile | |
| Audrey WarfieldGraham | Chief Officer | Profile | |
| Karen MD | Senior Strategy | Profile | |
| Richard Baxter | Senior Operation | Profile | |
| Todd Pettingill | Sr. Manager - Corporate Development and Investor Relations | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Ligand Pharmaceuticals Incorporated. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ligand Pharmaceuticals. If investors know Ligand will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ligand Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.032 | Earnings Share 2.49 | Revenue Per Share | Quarterly Revenue Growth 0.576 | Return On Assets |
The market value of Ligand Pharmaceuticals is measured differently than its book value, which is the value of Ligand that is recorded on the company's balance sheet. Investors also form their own opinion of Ligand Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ligand Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ligand Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ligand Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ligand Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ligand Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ligand Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.